Losartan Potassium Hctz
NDC Package 61919-732-90

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Losartan Potassium Hctz is hypertensionLosartan Potassium and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension. Marketed by Direct Rx, this product is identified by NDC 61919-732 and is authorized under FDA application ANDA091629.

Identification & Billing

NDC Package Code
61919-732-90
Package Description
90 TABLET, FILM COATED in 1 BOTTLE
Product Code
61919-732
11-Digit Billing Format
61919073290
RxNorm Crosswalk
  • RxCUI: 979464 - losartan potassium 100 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
  • RxCUI: 979464 - hydrochlorothiazide 12.5 MG / losartan potassium 100 MG Oral Tablet
  • RxCUI: 979464 - HCTZ 12.5 MG / Losartan K+ 100 MG Oral Tablet
  • RxCUI: 979464 - HCTZ 12.5 MG / Losartan Pot 100 MG Oral Tablet
  • RxCUI: 979464 - HCTZ 12.5 MG / losartan potassium 100 MG Oral Tablet

Clinical Specifications

Proprietary Name
Losartan Potassium Hctz
Dosage Form
-
Usage Information
HypertensionLosartan Potassium and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, and DOSAGE AND ADMINISTRATION).Hypertensive Patients with Left Ventricular HypertrophyLosartan Potassium and Hydrochlorothiazide Tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race, CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Losartan Potassium, Reduction in the Risk of Stroke, Race, and DOSAGE AND ADMINISTRATION.)

Regulatory & Marketing

Labeler Name
Direct Rx
FDA Application #
ANDA091629
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-18-2019
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61919-732-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Losartan Potassium Hctz, labeled by Direct Rx. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Direct Rx on April 18, 2019. The current certification is valid through December 31, 2022.

How is this Direct Rx product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61919073290. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61919-732-90
11-Digit CMS (5-4-2)
61919-0732-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.